{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-042822","form_type":"8-K","ticker":"DXR","cik":"0000027367","company_name":"DAXOR CORP","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.592599+00:00","generated_at":"2026-06-07T21:14:47.751946+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Daxor allocates $550K of May 2023 offering proceeds to hematocrit capability development","bullets":["Net proceeds of $3.56M from May 22, 2023 public offering of 410,260 shares at $9.75/share.","$550,000 reserved for proprietary hematocrit capability for next-generation technologies.","Development expected over 12 months, supported by Department of Defense efforts.","Funds are part of the previously stated use of proceeds for next-gen technology development."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-042822","json":"https://secwatch.observer/filing/0001493152-23-042822.json","markdown":"https://secwatch.observer/filing/0001493152-23-042822.md","text":"https://secwatch.observer/filing/0001493152-23-042822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/27367/000149315223042822/0001493152-23-042822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/27367/000149315223042822/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:14:47.751946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}